Highlights

  • Wall Street Zen modified its rating on KORU Medical Systems from Buy to Strong Buy.
  • Recent analyst commentary shows a mix of Buy, Hold, and Sell assessments.
  • The stock’s average price target stands near USD5.88, per consensus data.

In a recent sequence of research notes, several brokerages and ratings services updated their assessments of KORU Medical Systems, Inc. (NASDAQ:KRMD), reflecting a range of opinions on the medical device maker’s prospects. On Monday, investment analysis firm Wall Street Zen revised its view on KRMD, moving the stock from a Buy rating to a Strong Buy rating in its latest research note to investors. This adjustment represents a shift in the firm’s assessment of the company’s outlook based on its current analytical criteria.

Other research firms have issued differing views as well. For example, Weiss Ratings reiterated its Sell (D-) rating on KRMD shares in a note published on Wednesday, October 8, underscoring continued caution from that rating service. Meanwhile, Lake Street Capital raised its price objective on the stock from USD6.00 to USD8.00 and assigned a Buy rating in a report released on Monday, December 22. Canaccord Genuity Group also increased its target price, moving it from USD5.00 to USD6.00 while maintaining its Buy designation in mid-December.

Looking across the broader analyst community, one analyst currently rates KRMD with a Strong Buy rating, three have given Buy ratings, one holds a Hold rating, and one has issued a Sell rating. These varying assessments contribute to a consensus average rating described as a “Moderate Buy,” according to data compiled by MarketBeat, with an average price target near USD5.88 per share.

KORU Medical Systems develops and manufactures infusion medical devices used in the treatment of chronic illnesses such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy. Its portfolio includes products like the FREEDOM60 syringe infusion system, FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.

KRMD closed at USD 5.65 on January 12, 2026.